Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1612 1613 1622 1629
This examiner grants 26% of resolved cases
Sara Elizabeth Townsley is an examiner in Tech Center 1600, Art Unit 1612. The examiner has 392 resolved cases. The data shows an allowance rate of 25.5 percent and an interview lift of 49.1 percent. The median days to allowance for these cases is 1450.
The 49.1 percent interview lift is a significant figure when compared to the 25.5 percent base allowance rate. This indicates that conducting an interview is a method for increasing the likelihood of an allowance. The 1450 day median pendency is the timeframe applicants can expect when navigating the resolved cases handled by this examiner in Art Unit 1612. Practitioners can consider how these metrics influence the overall prosecution timeline.
With 392 resolved cases, the examiner's statistics provide a view of the prosecution landscape. Practitioners can use the 25.5 percent allowance rate to assess the probability of a grant. The 49.1 percent lift and the Tech Center 1600 environment are factors for prosecution strategy. These data points help in setting expectations for clients.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18018148 | SUBSTITUTED PYRROLO-PYRIDINONE DERIVATIVES AND THERAPEUTIC USES THEREOF | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 18043653 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | Final Rejection | SYNGENTA CROP PROTECTION AG |
| 18613849 | METHODS FOR ACCLIMATING TO RETINOID-CONTAINING COMPOSITIONS | Non-Final OA | Johnson & Johnson Consumer Inc. |
| 18245594 | PYRIDO[2,3-D]PYRIMIDIN-4-AMINES AS SOS1 INHIBITORS | Non-Final OA | Bayer Aktiengesellschaft |
| 18722304 | METHOD FOR SYNTHESIZING AN OXIME COMPRISING AN IMIDAZOLE GROUP AND METHOD FOR SYNTHESIZING A NITRILE OXIDE FROM SAID OXIME | Non-Final OA | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN |
| 18714642 | CDK4 INHIBITOR FOR THE TREATMENT OF CANCER | Non-Final OA | PFIZER INC. |
| 18917401 | COMPOSITION FOR PREVENTING OR IMPROVING SKIN-AGING CONTAINING A THYMOL ESTER-BASED COMPOUND | Non-Final OA | AMOREPACIFIC CORPORATION |
| 18247014 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Final Rejection | AstraZeneca AB |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy